Financial Wire

Swiss Market Index Recovers; Sika, PolyPeptide Group Shares Jump

-- The blue-chip Swiss Market Index bounced back on Tuesday, closing 0.94% higher, as investors digest the latest economy-related and corporate releases while keeping an eye on geopolitical developments.

On the macroeconomic front, the International Monetary Fund lowered its 2026 global growth forecast to 3.1% in its April World Economic Outlook report, down by 0.2 percentage point from its previous estimate, under the assumption that the ongoing conflict in the Middle East remains limited in duration and scope. For 2027, the global growth is still expected to stand at 3.2%.

For the euro area, the economic growth projections for 2026 and 2027 were both trimmed by 0.2 pp to 1.1% and 1.2%, respectively, while the estimates for the UK were cut by 0.5 pp and 0.2 pp to 0.8% and 1.3%.

Back home, Swiss President Guy Parmelin and Federal Councilor Karin Keller-Sutter are set to attend the 2026 IMF and World Bank Spring Meetings and G20 finance ministers meeting in the US this week, according to Switzerland's Federal Council. Swiss National Bank (SNBN.SW) Governing Board Chairman Martin Schlegel will also be part of the delegation.

"The Spring Meetings will focus on global economic and development policy challenges. In the current environment of geopolitical conflicts and trade tensions, it is particularly important for Switzerland to advocate reliable economic relations and open markets in multilateral bodies and bilateral contacts. Healthy public finances, price stability and a robust global monetary and financial system are also crucial for a resilient economy and lasting prosperity," the government said.

Over to corporates, Sika (SIKA.SW) reported a 7% year-over-year drop in first-quarter net sales to 2.49 billion francs. The result was dented by a foreign currency impact of 213 million francs, which the Swiss specialty chemicals group mainly attributed to the franc's strength against Asian currencies and the US dollar. For full-year 2026, the company reaffirmed its sales growth guidance of between 1% and 4% in local currencies. The stock gained 7.94% at closing.

PolyPeptide Group (PPGN.SW) also saw its shares rise 4.46% after disclosing that it is at an early stage of reviewing potential strategic options to further improve its long-term value for shareholders. Amid market chatter that it drew takeover interest from certain investors, the Swiss contract development and manufacturing organization noted that it has yet to decide on the review.

相關文章

Asia

Emerald Resources在3月份季度推進了西澳大利亞和柬埔寨的計畫。

根據週二提交給澳洲證券交易所的文件,Emerald Resources(ASX:EMR)表示,截至3月31日的季度,該公司在西澳大利亞的丁戈嶺金礦項目、梅莫特金礦項目、奧克瓦金礦以及柬埔寨的勘探權地均發現了金礦化。 丁戈嶺金礦計畫的鑽探結果顯示,在619公尺深處鑽遇了45公尺厚的礦層,金品位為4.1克/噸;其中包括在641公尺深處鑽遇的18.5公尺厚的礦層,金品位為5.2克/噸。 該公司表示,自1月礦產資源估算以來,丁戈嶺金礦計畫的勘探工作主要集中在露天礦坑的延伸和地下開採潛力兩方面。 文件也補充道,梅莫特金礦計畫的鑽探結果顯示,在40公尺深處鑽遇了2公尺厚的礦層,金品位為50.3克/噸;在1公尺深處鑽遇了14公尺厚的礦層,金品位為3.4克/噸。 奧克瓦烏金礦的礦脈交會點在 347 公尺處達到 3 公尺厚,金品位為每噸 59 公克;在 448 公尺處達到 22 公尺厚,金品位為每噸 1.9 公克。

$ASX:EMR
Asia

澳洲臨床實驗室否認維多利亞州最高法院提起的集體訴訟中的指控

根據澳洲證券交易所週二提交的文件顯示,澳洲臨床實驗室(ASX:ACL)否認了米歇爾·拉布-伊万諾夫(Michelle Raab-Ivanov)在維多利亞州最高法院提起的代表訴訟中的指控,併計劃「全力」應訴。 文件稱,訴訟代表的是2022年7月15日之前曾是該公司和/或其子公司Medlab Pathology的客戶,且其個人資訊在2022年2月Medlab Pathology遭受網路攻擊後受到影響的個人。 根據文件,該訴訟旨在根據涉嫌違反澳洲消費者法的行為,為受影響的個人尋求損害賠償。

$ASX:ACL
Asia

Challenger 將贖回所有未償還的 Challenger Capital 票據 3

根據週二提交給澳洲證券交易所的文件,Challenger(ASX:CGF)將於5月25日以每張100澳元的面額現金贖回所有未償還的Challenger Capital Notes 3。 此次贖回已獲得澳洲審慎監理局(APRA)的批准。 該公司表示,預計5月25日向所有截至5月15日登記在冊的持有人支付每張票據1.47澳元的最終分配。

$ASX:CGF